Delving into the Latest Updates on Cefoxitin Sodium with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

(6R,7S)-4-[(carbamoyloxy)methyl]-7-methoxy-8-oxo-7-[(thiophen-2-enyl)acetamido]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, CFX, Cefoxitin Sodium for Injetion

+ [10]

Target

PBPs

Mechanism

PBPs inhibitors(Bacterial penicillin-binding protein inhibitors), Cell wall inhibitors

Therapeutic Areas

Infectious DiseasesRespiratory DiseasesSkin and Musculoskeletal Diseases+ [2]

Active Indication

Bone and joint infectionsGynecological infectionIntraabdominal Infections+ [5]

Inactive Indication-

Originator Organization

Mylan NV

Active Organization

B. Braun Medical, Inc.Haikou Pharmaceutical Co. Ltd.

Inactive Organization

Mylan Institutional LLC

Drug Highest PhaseApproved

First Approval Date

US (18 Oct 1978),

Bone and joint infectionsGynecological infectionIntraabdominal Infections+ [4]

Regulation-

Login to view timeline

Structure

Molecular FormulaC16H17N3NaO7S2

InChIKeyMRJZOFPLZPTXGN-XMZRARIVSA-N

CAS Registry33564-30-6

View All Structures (2)

Mycobacterium abscessus (MABS) is a group of rapid-growing, multi-drug resistant non-tuberculous mycobacteria (NTM) causing infections in humans. MABS pulmonary disease (MABS-PD) can result in significant morbidity, increased healthcare utilisation, accelerated lung function decline, impaired quality of life, more challenging lung transplantation, and increased mortality. While the overall numbers affected is small, the prevalence of infections is increasing worldwide. The Finding the Optimal Regimen for Mycobacterium abscessus Treatment (FORMaT) trial aims to produce high quality evidence for the best treatment regimens to maximise health outcomes and minimise toxicity and treatment burden, as well as developing biomarkers (serology, gene expression signatures, and radiology) to guide decisions for starting treatment and measuring disease severity in patients with MABS PD.

Start Date02 Mar 2020

Sponsor / Collaborator

The University of Queensland

[+12]

100 Clinical Results associated with Cefoxitin Sodium

Login to view more data

100 Translational Medicine associated with Cefoxitin Sodium

Login to view more data

100 Patents (Medical) associated with Cefoxitin Sodium

Login to view more data

5,573

Literatures (Medical) associated with Cefoxitin Sodium

31 Dec 2024·Libyan Journal of Medicine

Prevalence of multi-drug resistant bacteria in intensive care units at Tripoli University Hospital, Tripoli, Libya

Article

Author: El Meshri, Salah Edin ; ELmaryul, Abubaker ; Ermithi, Otman ; Alhudiri, Inas ; Ibrahim, Khaled ; Belaid, Saadeddin ; Elfahem, Abdurrezagh ; Almadah, Suad ; Elzagheid, Adam ; Almaghrabi, Mahmoud ; Thwood, Dalal ; El Salabi, Allaaeddin ; ELgheriani, Hajer ; Zaghdani, Ahmed ; Elgadiym, Zaynab ; Salem, Mohamed ; Rayes, Abdunnabi ; Habibi, Abdulraouf

Among hospitalized patients worldwide, infections caused by multidrug-resistant (MDR) bacteria are a major cause of morbidity and mortality. This study aimed to isolate MDR bacteria from five intensive care units (ICUs) at Tripoli University Hospital (TUH). A prospective cross-sectional study was conducted over a seven-month period (September 2022 to March 2023) across five ICUs at TUH. A total of 197 swabs were collected from Patients', healthcare workers' and ICUs equipment. Samples collected from patients were nasal swabs, oral cavity swabs, hand swabs, sputum specimens, skin swabs, umbilical venous catheter swabs, and around cannula. Swabs collected from health care workers were nasal swabs, whereas ICUs equipment's samples were from endotracheal tubes, oxygen masks, and neonatal incubators. Identification and antimicrobial susceptibility test was confirmed by using MicroScan auto SCAN 4 (Beckman Coulter). The most frequent strains were Gram negative bacilli 113 (57.4%) with the predominance of Acinetobacter baumannii 50/113 (44%) followed by Klebsiella pneumoniae 44/113 (40%) and Pseudomonas aeruginosa 6/113 (5.3%). The total Gram positive bacterial strains isolated were 84 (42.6%), coagulase negative Staphylococci 55 (66%) with MDRs (89%) were the most common isolates followed by Staphylococcus aureus 15 (17.8%). Different antibiotics were used against these isolates; Gram- negative isolates showed high resistance rates to ceftazidime, gentamicin, amikacin and ertapenem. A. baumannii were the most frequent MDROs (94%), and the highest resistance rates in Gram-positive strains were observed toward ampicillin, oxacillin, ampicillin/sulbactam and Cefoxitin, representing 90% of total MDR Gram-positive isolates. ESBL and MRS were identified in most of strains. The prevalence of antibiotic resistance was high for both Gram negative and Gram positive isolates. This prevalence requires strict infection prevention and control intervention, continuous monitoring, implementation of effective antibiotic stewardship, immediate, concerted and collaborative action to monitor its prevalence and spread in the hospital.

09 Dec 2024·Journal of Biomolecular Structure and Dynamics

Unraveling the mechanisms of Cefoxitin resistance in methicillin-resistant Staphylococcus aureus (MRSA): structural and molecular simulation-based insights

Article

Author: M Alshabrmi, Fahad ; Alatawi, Eid A.

Methicillin-resistant Staphylococcus aureus (MRSA) severely affects human health, including the skin glands, nasal cavity, wound infections, bone infections, and pneumonia. Among the most effective MRSA drugs, Cefoxitin also develops resistance due to mutations in the mecA gene. Four mutations at positions E229K, E239R, G246K, and E447K are classified as high-level resistance mutations. However, the resistance mechanism of MRSA towards Cefoxitin caused by these mutations is still unclear, as there is less information available regarding the structural and functional effects of the mutations against Cefoxitin. Therefore, our present study was designed to explore the mechanisms of binding interactions between wild-type and mutated PBP2a against Cefoxitin using molecular docking and MD simulations. Subsequently, we identified that the mutant form of PBP2a affects the activity of Cefoxitin. Interestingly, the binding of Cefoxitin with G246K and E239R mutants demonstrates unstable behavior compared to E447K-Cefoxitin and E229K-Cefoxitin. In this study, we propose the resistance mechanism of Cefoxitin at the atomic level. The proposed drug-resistance mechanism will provide valuable guidance for the design of MRSA drugs. This research might provide a new framework for designing new agents against the mutated form of PBP2a.Communicated by Ramaswamy H. Sarma.

01 Dec 2024·Molecular Biology Reports

Nasal carriage of virulent and multidrug resistant Staphylococcus aureus: a possible comorbidity of COVID-19

Article

Author: Omolopo, Ibilola ; Olanlege, Abdul-Lateef Olatunde ; Bamidele, Tajudeen Akanji ; Salako, Babatunde Lawal ; Raheem, Toyosi ; Edu-Muyideen, Idowu ; Iwalokun, Bamidele ; Adesesan, Adesegun ; Onyeaghasiri, Faustina ; Tajudeen, Ahmed Oluwasegun ; Aiyedogbon, Adenike ; Abioye, Aminah ; Fowora, Muinah Adenike

BACKGROUNDStaphylococcus aureus (S. aureus) associated with COVID-19 has not been well documented. This cross-sectional study evaluated the association between nasal S. aureus carriage and COVID-19.METHODS AND RESULTSNasopharyngeal samples were collected from 391 participants presenting for COVID-19 test in Lagos, Nigeria, and S. aureus was isolated from the samples. Antimicrobial susceptibility test was done by disc diffusion method. All S. aureus isolates were screened for the presence of mecA, panton-valentine leucocidin (PVL) and toxic shock syndrome toxin (TSST) virulence genes by polymerase chain reaction. Staphylococcal protein A (spa) typing was conducted for all the isolates. Participants with COVID-19 had double the prevalence of S. aureus (42.86%) compared to those who tested negative (20.54%). A significant association was seen between S. aureus nasal carriage and COVID-19 (p = 0.004). Antimicrobial sensitivity results showed resistance to oxacillin (100%), cefoxitin (53%), and vancomycin (98.7%). However, only 41% of the isolates harbored the mecA gene, with SCCmecV being the most common SCCmec type. There was no association between the carriage of virulence genes and COVID-19. A total of 23 Spa types were detected, with t13249 and t095 being the two most common spa types.CONCLUSIONThis study examined the association between nasal S. aureus carriage and SARS-COV-2 infection. Further research is required to fully explore the implications of S. aureus co-infection with COVID-19.

100 Deals associated with Cefoxitin Sodium

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D00913	Cefoxitin Sodium	J01DC01	DB01331

R&D Status

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Bone and joint infections	US	B. Braun Medical, Inc.	10 Mar 2006
Gynecological infection	US	B. Braun Medical, Inc.	10 Mar 2006
Intraabdominal Infections	US	B. Braun Medical, Inc.	10 Mar 2006
Lower Respiratory Tract Infections	US	B. Braun Medical, Inc.	10 Mar 2006
Sepsis	US	B. Braun Medical, Inc.	10 Mar 2006
Skin and skin structure infections	US	B. Braun Medical, Inc.	10 Mar 2006
Urinary Tract Infections	US	B. Braun Medical, Inc.	10 Mar 2006
Bacterial Infections	CN	Haikou Pharmaceutical Co. Ltd.	01 Jan 1995

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03306290 (Pubmed) Manual	Not Applicable	Obesity	123	Cefoxitin	(bmedssuldj) = pgrijzpzzk xqsijcabht (iutocmqbaz, 6.1) View more	Positive	15 Mar 2024
AAAAI2024	Not Applicable	Anaphylaxis	-	Cefazolin	wxmumhttfg(xmvktztoyb) = vfsdwmzptr jrrltxmxuu (ekzqcvoful )	-	23 Feb 2024
				Cefoxitin	wxmumhttfg(xmvktztoyb) = nvcyhtikdt jrrltxmxuu (ekzqcvoful )
NCT02958059 (Pubmed) Manual	Not Applicable	Infectious Diseases	349	cefoxitin	vvnsphnbor(sqyqeqqajh) = svtntosjfa ucuuazryoj (sbdxqtutdb ) View more	Positive	01 Jan 2024
				Placebo	vvnsphnbor(sqyqeqqajh) = tzkbmlwukw ucuuazryoj (sbdxqtutdb ) View more
NCT02800785 (CODA, CTgov)	Not Applicable	Appendicitis	1,552	Cefoxitin, Ertapenem, Moxifloxacin, Tigecycline, Ticarcillin-Clavulanic Acid; Metronidazole plus Cefazolin, Cefuroxime, Ceftriaxone, Cefotaxime, Ciprofloxacin, or Levofloxacin (Antibiotics Therapy Arm)	fressqcxnv(utvgsolmdp) = tsbsgukocm qniypwioiz (nfgcszkoju, swmkovhfoy - aofltvqrzg) View more	-	18 Apr 2023
				Appendectomy (Appendectomy Arm)	fressqcxnv(utvgsolmdp) = myesrthttx qniypwioiz (nfgcszkoju, myaxomzeus - ynaiykgrpt) View more
ASN2022	Not Applicable	Acute Kidney Injury	-	Cefoxitin	sqkzkmxtqn(brobbjrzuo) = pseudo-AKI from cefoxitin coaatruiop (aystfjuqin )	-	03 Nov 2022